alosetron IBS-D women
Selected indexed studies
- Novel Therapies in IBS-D Treatment. (Curr Treat Options Gastroenterol, 2015) [PMID:26432092]
- A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. (Am J Gastroenterol, 2007) [PMID:17509028]
- Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. (Aliment Pharmacol Ther, 2012) [PMID:22779693]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Novel Therapies in IBS-D Treatment. (2015) pubmed
- A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. (2007) pubmed
- Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. (2012) pubmed
- The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). (2015) pubmed
- Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. (2011) pubmed
- Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. (2019) pubmed
- Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new? (2024) pubmed
- Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. (2004) pubmed
- Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. (2019) pubmed
- Management of irritable bowel syndrome with diarrhea: focus on eluxadoline. (2021) pubmed